JP2024543973A - ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト - Google Patents

ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト Download PDF

Info

Publication number
JP2024543973A
JP2024543973A JP2024532491A JP2024532491A JP2024543973A JP 2024543973 A JP2024543973 A JP 2024543973A JP 2024532491 A JP2024532491 A JP 2024532491A JP 2024532491 A JP2024532491 A JP 2024532491A JP 2024543973 A JP2024543973 A JP 2024543973A
Authority
JP
Japan
Prior art keywords
pharma
acceptable salt
ceutically acceptable
compound according
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543973A5 (https=
Inventor
ベンダー，アロン，エム．
スポック，マシュー
コルクマズ－ヴァイシス，メリッサ，エー．
マリンキー，コリ，エー．
コン，ピー．，ジェフリー
リンズレー，クレイグ，ダブリュー．
Original Assignee
ヴァンダービルト ユニヴァーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァンダービルト ユニヴァーシティ filed Critical ヴァンダービルト ユニヴァーシティ
Publication of JP2024543973A publication Critical patent/JP2024543973A/ja
Publication of JP2024543973A5 publication Critical patent/JP2024543973A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2024532491A 2021-12-01 2022-12-01 ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト Pending JP2024543973A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163284750P 2021-12-01 2021-12-01
US63/284,750 2021-12-01
PCT/US2022/051493 WO2023102100A1 (en) 2021-12-01 2022-12-01 Antagonists of the muscarinic acetylcholine receptor m4

Publications (2)

Publication Number Publication Date
JP2024543973A true JP2024543973A (ja) 2024-11-26
JP2024543973A5 JP2024543973A5 (https=) 2025-12-08

Family

ID=84943708

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532491A Pending JP2024543973A (ja) 2021-12-01 2022-12-01 ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト

Country Status (10)

Country Link
US (1) US20250145595A1 (https=)
EP (1) EP4441046A1 (https=)
JP (1) JP2024543973A (https=)
KR (1) KR20240112343A (https=)
CN (2) CN116669737A (https=)
AU (1) AU2022400780A1 (https=)
CA (1) CA3241298A1 (https=)
IL (1) IL313219A (https=)
MX (1) MX2024006718A (https=)
WO (1) WO2023102100A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018300980A1 (en) 2017-07-12 2020-01-02 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
IL273924B2 (en) 2017-10-20 2024-07-01 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
CA3155864A1 (en) 2019-10-04 2021-04-08 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
EP4491228A3 (en) * 2020-12-22 2025-04-23 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018003417B1 (pt) * 2016-06-22 2023-10-24 Vanderbilt University Composto modulador alostérico positivo do receptor muscarínico de acetilcolina m4 e composição farmacêutica que o compreende
JP2020530451A (ja) * 2017-08-08 2020-10-22 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
IL273924B2 (en) * 2017-10-20 2024-07-01 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
WO2021119254A1 (en) * 2019-12-10 2021-06-17 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
US20230183218A1 (en) * 2020-04-24 2023-06-15 Vanderbilt University Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
EP4139303A1 (en) * 2020-04-24 2023-03-01 Vanderbilt University Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4

Also Published As

Publication number Publication date
AU2022400780A1 (en) 2024-06-20
CN118541365A (zh) 2024-08-23
MX2024006718A (es) 2024-08-09
EP4441046A1 (en) 2024-10-09
CA3241298A1 (en) 2023-06-08
KR20240112343A (ko) 2024-07-18
IL313219A (en) 2024-07-01
US20250145595A1 (en) 2025-05-08
CN116669737A (zh) 2023-08-29
WO2023102100A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
EP4267569B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
JP7572734B2 (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
US20250145595A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
AU2021261002A1 (en) Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
JP2023522959A (ja) ムスカリンアセチルコリン受容体ｍ４のアンタゴニストとしての縮合置換ヒドロピロール
WO2022216655A1 (en) N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders
US20230150986A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
AU2021381350A9 (en) Antagonists of the muscarinic acetylcholine receptor m4
WO2022212819A1 (en) Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4
WO2022261427A1 (en) (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders
WO2022036177A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
HK40121280A (en) Antagonists of the muscarinic acetylcholine receptor m4
HK40115503A (zh) 毒蕈硷型乙醯胆硷受体m4的拮抗剂
HK40097532A (zh) 毒蕈碱型乙酰胆碱受体m4的拮抗剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251128